HIV is treated with antiretroviral therapy (ART), a combination of medications taken daily or, in some cases, given as injections every one to two months. These drugs don’t cure HIV, but they stop the virus from multiplying in your body, allowing your immune system to recover and keeping you healthy long-term. Most people who start treatment and stick with it can reduce the virus to undetectable levels within a few months.
How Antiretroviral Drugs Work
HIV hijacks your immune cells and uses their machinery to copy itself. Antiretroviral drugs interrupt this process at different stages. Some block the virus from entering your cells in the first place. Others prevent the virus from converting its genetic material into DNA your cells can read. A third group stops viral DNA from being inserted into your cell’s own DNA. And a fourth group keeps newly made virus particles from maturing into copies that can infect more cells.
Because the virus can develop resistance to any single drug, treatment always involves a combination of two or three medications that attack different stages of the viral lifecycle. This makes it far harder for the virus to evolve its way around treatment. Nearly half of all approved HIV drugs target the step where the virus copies its genetic material, which gives doctors the most options in that category.
First-Line Treatment Regimens
If you’re starting treatment for the first time, current U.S. guidelines recommend one of three regimens. All of them are built around a class of drugs called integrase inhibitors, which block HIV from inserting itself into your DNA. The recommended options are:
- Biktarvy: A single pill taken once daily that combines three drugs (bictegravir, tenofovir alafenamide, and emtricitabine).
- Dolutegravir plus tenofovir and emtricitabine (or lamivudine): Either a single pill or two pills taken once daily.
- Dovato: A two-drug regimen (dolutegravir and lamivudine) in one pill, suitable for most people, though not recommended if your viral load is above 500,000 copies per milliliter or if you have hepatitis B.
These regimens were chosen because they have strong evidence of durability, manageable side effects, and simple dosing. For most people, treatment comes down to taking one or two pills at the same time each day.
Long-Acting Injectable Treatment
For people who are already on pills and have an undetectable viral load, there’s now an injectable option that eliminates daily dosing. The regimen combines two drugs (cabotegravir and rilpivirine) given as two shots in the buttock muscle, administered by a healthcare provider either once a month or once every two months.
The every-two-month schedule starts with two monthly loading doses to build up drug levels in your body, then switches to dosing every eight weeks. There’s a seven-day window on either side of your scheduled appointment for flexibility. To qualify, you need to have maintained viral suppression for at least three to six months on your current regimen, with no history of treatment failure or resistance to either drug class.
How Doctors Know Treatment Is Working
Two blood tests tell the story of how well your treatment is working: viral load and CD4 count.
Viral load measures the amount of HIV in your blood. The goal is to reach viral suppression, defined as fewer than 200 copies of HIV per milliliter of blood. With effective treatment, most people go even lower, reaching what’s called “undetectable,” meaning standard lab tests can’t find the virus at all. Reaching undetectable isn’t just good for your health. It also means you won’t transmit HIV to sexual partners.
CD4 count measures the immune cells HIV targets. A healthy person without HIV typically has between 500 and 1,500 of these cells per cubic millimeter of blood. In the first year of treatment, most people see their CD4 count rise by 50 to 150 cells, with the fastest gains in the first three months. Once your count climbs above 300 and your viral load stays suppressed, your doctor may stop checking CD4 levels regularly since they no longer add much useful information at that point.
When Treatment Stops Working
If your viral load rises above 200 copies per milliliter while you’re on treatment, that’s considered virologic failure. The most common reason is missed doses, but the virus can also develop resistance mutations that make your medications less effective.
When this happens, your doctor will order a resistance test, typically a genotypic test that sequences the virus’s genes to identify specific mutations. This information guides the switch to a new combination of drugs that the virus hasn’t developed defenses against. For people on their first or second regimen, genotypic testing alone is usually enough. For those with a longer treatment history and potentially complex resistance patterns, a second type of test (phenotypic testing) may be added to get a fuller picture.
Treatment isn’t delayed while waiting for test results. If you’re newly diagnosed, your doctor will start you on a regimen right away and adjust if the results show resistance to any of the drugs.
Treatment During Pregnancy
Antiretroviral therapy during pregnancy prevents the virus from passing to the baby. Without treatment, the risk of transmission is significant. With it, the risk drops to very low levels. The same classes of drugs are used, though some specific medications are preferred over others based on safety data in pregnancy.
Drugs with the strongest safety track record in pregnant people include tenofovir disoproxil fumarate, emtricitabine, lamivudine, and dolutegravir. Some older protease inhibitors have been linked to an increased risk of preterm birth and are no longer recommended except in unusual circumstances. If you’re already on a suppressive regimen when you become pregnant, your doctor will review your medications and may adjust them based on pregnancy-specific guidelines.
Long-Term Side Effects to Watch For
Modern HIV drugs are far better tolerated than earlier generations, but long-term use can still affect your metabolism. The most common concerns include changes in cholesterol and triglyceride levels, shifts in how your body stores fat (some areas gain fat while others lose it), bone thinning, and insulin resistance that can lead to diabetes over time. Protease inhibitors have the strongest association with rising cholesterol and triglycerides. Other drug classes tend to cause only modest lipid changes.
These metabolic effects don’t happen to everyone, and they can often be managed with lifestyle changes or by switching to a different drug combination. Your doctor will monitor bloodwork regularly, especially in the first year, to catch these shifts early. The cardiovascular risk from untreated HIV is far greater than the metabolic risk from the medications themselves.
Paying for Treatment
HIV treatment is expensive without assistance, but several programs exist to close the gap. The Ryan White HIV/AIDS Program, funded by the federal government, covers people who are low-income and either uninsured or underinsured. Services include the AIDS Drug Assistance Program, which pays for medications directly, as well as health insurance premium assistance, medical case management, mental health services, dental care, and substance abuse treatment.
Beyond medical costs, the program also covers practical needs that affect a person’s ability to stay in care: transportation to appointments, food assistance, housing support, emergency financial help, and legal services. A case manager can help you understand what you’re eligible for and assist with applications. Eligibility is based on your HIV diagnosis, income level, and insurance status, with specific thresholds varying by state.